Mutations in SARS-CoV-2 spike protein receptor-binding domains may result in escape variants resistant to therapeutics and vaccines (IMAGE)

PLOS

Mutations in SARS-CoV-2 spike protein receptor-binding domains may result in escape variants resistant to therapeutics and vaccines

Caption

Monoclonal antibody-mediated neutralization of SARS-CoV-2: The left panel illustrates the morphology of the SARS-CoV-2 virus and displaying the trimeric spike protein on its surface bound with antibodies. The right panel depicts the zoomed view of the trimeric spike protein (top view) in prefusion state bound with monoclonal antibodies. Each monomer of the spike protein shows the receptor binding domain (RBD) in green, orange and magenta, which contains a receptor binding motif in cyan on the top. Mutations emerged in the SARS-CoV-2 Omicron variants are shown in red. Here, the C309 (a parent of VIR-7831 or Sotrovimab) antibody is shown in blue, which is one of the antibodies in clinical use that is minimally impacted by the Omicron variant mutations.

Credit

Piyush Prakash, Anshumali Mittal, Vikash Verma, Arun Khatri (CC BY 4.0, https://creativecommons.org/licenses/by/4.0/)

Usage Restrictions

Credit must be given to the creator.

License

CC BY

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.